First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC

First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC
The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of resistant ovarian cancer. The new partnership was developed to test ZEN-3694 across several cancer indications. For this upcoming study, the NCI also is collaborating with Bristol Myers Squibb, the developer of Opdivo and Yervoy. “This collaboration will significantly supplement our efforts in expanding the portfolio of indications for ZEN-3694 both as a single agent and as a component of novel combination regimens with other therapies,” Donald McCaffrey, the president and the CEO of Zenith, said in a press release. “NCI’s interest validates our belief that ZEN-3694 is a leading and differentiated BET inhibitor,” McCaffrey added. ZEN-3694 is an orally administered small inhibitor of the BET proteins, which regulate the production of genes that are needed for the survival and excessive proliferation of cancer cells. Over the last years, scientists have been testing BET inhibitors as a means to treat a broad range of cancers. While limited anti-cancer activity is observed when used as single agents, these inhibitors have shown promising effects in combination therapies. BET inhibitors also seem to prevent resistance to various cancer treatments, according to Zenith. The company's compound, ZEN-3694, was found to restore sensitivity to prostate cancer therapies that target the androgen receptor. It also was shown to increase the sensitivity of breast cancer patients without BRCA mutations to a new class of therapies called PARP inhibitors. “Our therapy
Subscribe or to access all post and page content.